Bipolar Depression Clinical Trial
Official title:
Neuroimaging Studies of the Treatment of Bipolar Depression With Citalopram
| NCT number | NCT01639482 |
| Other study ID # | 2009P002712 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | April 2010 |
| Est. completion date | December 2013 |
| Verified date | March 2019 |
| Source | Massachusetts General Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Regional metabolic changes associated with response to 6 weeks of citalopram treatment, using 18-Fluorodeoxyglucose Positron Emission Tomography imaging, will be characterized (FDG PET).
| Status | Completed |
| Enrollment | 60 |
| Est. completion date | December 2013 |
| Est. primary completion date | December 2013 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 64 Years |
| Eligibility |
Inclusion Criteria: - Current age 18-64 years; DSM-IV diagnosis of BPD, type-I, or type-II; Enrolled in the Citalopram Study at Tufts Medical Center Exclusion Criteria: - Current pregnancy, or inability to utilize contraception, The presence of any metallic implants, History of claustrophobia |
| Country | Name | City | State |
|---|---|---|---|
| United States | Massachusetts General Hospital - East | Charlestown | Massachusetts |
| Lead Sponsor | Collaborator |
|---|---|
| Massachusetts General Hospital |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | rCMRglu | regional glucose metabolism | pre and post-treatment |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03256162 -
Ketamine as an Adjunctive Therapy for Major Depression
|
Phase 1 | |
| Recruiting |
NCT03396744 -
Bright Light Therapy in the Treatment of Non-seasonal Bipolar Depression
|
Phase 1/Phase 2 | |
| Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
| Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
| Completed |
NCT02363738 -
12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression
|
Phase 2 | |
| Terminated |
NCT01807741 -
Asenapine for Bipolar Depression
|
Phase 2 | |
| Recruiting |
NCT01213121 -
Neurophysiologic Changes in Patients With Bipolar Depression
|
Phase 4 | |
| Completed |
NCT01919892 -
Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium
|
Phase 4 | |
| Completed |
NCT00762268 -
A Trial of SAMe for Treatment-Resistant Bipolar Depression
|
N/A | |
| Terminated |
NCT00566111 -
Ceftriaxone in the Management of Bipolar Depression
|
N/A | |
| Terminated |
NCT00217217 -
Low Field Magnetic Stimulation Treatment for Bipolar Depression
|
Phase 3 | |
| Recruiting |
NCT04998773 -
Efficacy and Biomarkers of Response of TBS in Treatment Resistant Depression
|
N/A | |
| Recruiting |
NCT04939649 -
Ketamine as an Adjunctive Therapy for Major Depression (2)
|
Phase 3 | |
| Completed |
NCT03658824 -
Behavioural Activation for Bipolar Depression: A Case Series
|
N/A | |
| Suspended |
NCT03674671 -
Ketamine Versus Electroconvulsive Therapy in Depression
|
Phase 3 | |
| Recruiting |
NCT05340686 -
Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression
|
N/A | |
| Recruiting |
NCT05296356 -
OSU6162 in Bipolar Depression (OBID)
|
Phase 2 | |
| Recruiting |
NCT03711019 -
Efficacy of Convulsive Therapies During Continuation
|
N/A | |
| Completed |
NCT02088580 -
Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients
|
N/A | |
| Terminated |
NCT00272025 -
Treatment Resistant Bipolar Depression
|
Phase 1 |